Effect of HER2-targeted therapy on PDX and PDX-derived organoids generated from HER2-positive salivary duct carcinoma

被引：2
|
作者：
Aoyama, Jun [1 ]
Nojima, Yusuke [1 ]
Sano, Daisuke [1 ,2 ,3 ]
Hirai, Yuri [1 ]
Kijima, Natsumi [1 ]
Aizawa, Yoshihiro [1 ]
Takada, Kentaro [1 ]
Hatano, Takashi [1 ]
Takahashi, Hideaki [1 ]
Nishimura, Goshi [1 ]
Oridate, Nobuhiko [1 ,2 ]
机构：
[1] Yokohama City Univ, Grad Sch Med, Dept Biol & Funct Head & Neck, Yokohama, Japan
[2] Yokohama City Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Yokohama, Japan
[3] Yokohama City Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 3-9 Fukuura,Kanazawa Ku, Yokohama 2360004, Japan
来源：
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2023年 / 45卷 / 07期
基金：
日本学术振兴会;
关键词：
HER2; lapatinib; patient-derived organoid; salivary duct carcinoma; salivary gland cancer; FACTOR RECEPTOR EGFR; LAPATINIB; BREAST; TRASTUZUMAB; RESISTANCE; INHIBITOR; GW572016; HEAD;
D O I：
10.1002/hed.27395
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
BackgroundWe previously established a patient-derived xenograft (PDX) model, patient-derived organoids (PDOs), and PDX-derived organoids (PDXOs) for salivary duct carcinoma (SDC). Using these models, this study examined the therapeutic effect of human epidermal growth factor receptor 2 (HER2) blockade on HER2-positive SDC. MethodsThe therapeutic effect of lapatinib was assessed in SDC PDXOs with regards to cell growth, receptor/downstream signaling molecule expression, phosphorylation levels, and apoptosis. Effect of lapatinib treatment was evaluated in vivo in SDC PDX mice. ResultsThe siRNA knockdown of HER2 and lapatinib suppressed cell proliferation in SDC PDXOs. Lapatinib inhibited the phosphorylation of HER2 and its downstream targets, and induced apoptosis in SDC PDXOs. Lapatinib also significantly reduced tumor volumes compared with that of the control in SDC PDX mice. ConclusionFor the first time, we demonstrated the efficacy of anti-HER2 therapy in HER2-positive SDC using preclinical models of SDC PDX and PDXO.
引用
收藏
页码：1801 / 1811
页数：11
相关论文
共 50 条
  • [31] Overall Survival for HER2-Positive Breast Cancer Patients in the HER2-Targeted Era: Evidence From a Population-Based Study
    Marczyk, Vicente Rodrigues
    Rosa, Daniela Dornelles
    Maia, Ana Luiza
    Goemann, Iuri Martin
    CLINICAL BREAST CANCER, 2022, 22 (05) : 418 - 423
  • [32] Neratinib and the Role of Anti-HER2 Therapy in Salivary Duct Carcinoma
    Napolitano, Martina
    Trudu, Lucia
    Martinelli, Enrica
    Santini, Chiara
    Dominici, Massimo
    Bertolini, Federica
    CANCER REPORTS, 2025, 8 (01)
  • [33] HER2-targeted ADC DX126-262 combined with chemotherapy demonstrates superior antitumor efficacy in HER2-positive gastric cancer
    Cai, Xiaobo
    Cao, Min
    Yang, Qingliang
    Yu, Xiazhen
    Feng, Xin-Hua
    Zhao, Robert Yongxin
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (12):
  • [34] HER2/HER3-positive metastatic salivary duct carcinoma in the pleural effusion: A case report
    Murata, Kazuya
    Kawahara, Akihiko
    Ono, Takeharu
    Takase, Yorihiko
    Abe, Hideyuki
    Naito, Yoshiki
    Akiba, Jun
    DIAGNOSTIC CYTOPATHOLOGY, 2018, 46 (05) : 429 - 433
  • [35] HER2-positive metastatic, parotid salivary duct carcinoma treated with a trastuzumab/pertuzumab-based chemotherapy: A case report
    Longo, Raffaele
    Legros, Pierre-Olivier
    Talbi, Marouane
    Wagner, Marc
    Paraschiv, Elena-Adinisia
    Campitiello, Marco
    Plastino, Francesca
    Rozzi, Antonio
    CLINICAL CASE REPORTS, 2020, 8 (12): : 2877 - 2881
  • [36] Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
    Dieci, M. V.
    Prat, A.
    Tagliafico, E.
    Pare, L.
    Ficarra, G.
    Bisagni, G.
    Piacentini, F.
    Generali, D. G.
    Conte, P.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2016, 27 (10) : 1867 - 1873
  • [37] First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy
    Rier, Hanah N.
    Levin, Mark-David
    van Rosmalen, Joost
    Bos, Monique M. E. M.
    Drooger, Jan C.
    de Jong, Paul
    Portielje, Johanneke E. A.
    Elsten, Elisabeth M. P.
    ten Tije, Albert-Jan
    Sleijfer, Stefan
    Jager, Agnes
    ONCOLOGIST, 2017, 22 (08) : 901 - 909
  • [38] HER2-Targeted Therapy-From Pathophysiology to Clinical Manifestation: A Narrative Review
    Slavcheva, Svetoslava Elefterova
    Angelov, Atanas
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (12)
  • [39] ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy
    McAfee, John L.
    Hoda, Raza S.
    Hoyle, Carrie
    McCoy, Lauren
    Sprague, Cathy
    Reddy, Chandana A.
    Koyfman, Shlomo A.
    Geiger, Jessica L.
    Komforti, Miglena K.
    Griffith, Christopher C.
    MODERN PATHOLOGY, 2023, 36 (10)
  • [40] Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
    Sinead Toomey
    Alexander J. Eustace
    Joanna Fay
    Katherine M. Sheehan
    Aoife Carr
    Malgorzata Milewska
    Stephen F. Madden
    Ausra Teiserskiene
    Elaine W. Kay
    Norma O’Donovan
    William Gallagher
    Liam Grogan
    Oscar Breathnach
    Janice Walshe
    Catherine Kelly
    Brian Moulton
    M. John Kennedy
    Guiseppe Gullo
    Arnold D. Hill
    Colm Power
    Deirdre Duke
    Niamh Hambly
    John Crown
    Bryan T. Hennessy
    Breast Cancer Research, 19
12345